Abstract: A sustained-release pharmaceutical composition comprising a highly soluble pharmaceutical agent, such as selegiline, in a pharmaceutical carrier comprising a hydrophilic polymer dispersed in a hydrophobic matrix. A hydrophilic microenvironment is created in a hydrophobic matrix by incorporating hydrophilic polymers within a hydrophobic matrix. Optionally, a binder, preferably a polyhydroxylated compound, ca also be added.
Type:
Grant
Filed:
March 28, 1994
Date of Patent:
January 16, 1996
Assignee:
Pharmavene, Inc.
Inventors:
Edward M. Rudnic, John A. McCarty, George W. Belenduik
Abstract: A pharmaceutical preparation including a pharmaceutical agent incorporated into particles comprising (i) a core formed from a hydrophilic material, a hydrophobic material or a hydrophobic emulsion or dispersion and (ii) an alternating sequence of hydrophilic/hydrophobic layers thereon such that there is a hydrophilic/hydrophobic interface between the core and each succeeding layer.
Type:
Grant
Filed:
April 7, 1994
Date of Patent:
September 5, 1995
Assignee:
PharmaVene, Inc.
Inventors:
George W. Belenduik, Edward M. Rudnic, John A. McCarty
Abstract: A pharmaceutical preparation including a drug incorporated into hydrophobic particles comprised of long chain carboxylic acid or ester thereof or long chain alcohol, wherein the particles are incorporated into a unit dosage form and are individually coated with an enteric coating and/or the unit dosage form includes an enteric protective material.
Type:
Grant
Filed:
March 18, 1994
Date of Patent:
July 4, 1995
Assignee:
Pharmavene, Inc.
Inventors:
Edward M. Rudnic, John A. McCarty, George W. Belenduik
Abstract: The present invention relates to a composition and method of treating a patient by administering carbamazepine in a pharmaceutical dosage form capable of maintaining the patient's blood concentration at from about 4 .mu.g/ml to about 12 .mu.g/ml over at least a 12 hour period, where the blood concentration of carbamazepine does not vary by more than 60 percent.
Abstract: Butyrylcholinesterase is produced in a purity of at least 90% by subjecting plasma fraction IV-4 alone or in admixture with fraction IV-1 to both anion exchange chromatography and affinity chromatography.
© 2024 Justia
